Severe Preeclampsia Clinical Trial
The purpose of this study, to investigate whether severity of preeclampsia is associated with altered levels of heavy metals (Cd, Hg, arsenic and Pb) in maternal blood, fetal blood, and maternal hair.
The unfavorable effects of heavy metals on human health is well known. The main threats to
human health from heavy metals are associated with exposure to lead, cadmium, mercury and
arsenic. They may be toxic at the levels previously thought to have no adverse effect on
human.In utero environmental exposures can have long term consequences to health and
development.İn spite of what is known about the neurotoxicity from exposure to heavy metals,
the health effects from co-exposure to these chemicals and the biologically effective doses
are not known exactly.
Preeclampsia is associated with increased maternal and infant mortality and morbidity. The
exact etiology is not clear. Several evidences indicate that various environmental factors
and elements may play a role in pre-eclampsia.
significant increase in Pb, cadmium (Cd), copper (Cu) and magnesium (Mg) and decrease in
zinc (Zn) in amniotic fluid are associated with preeclampsia. Pb as this metal has well
known adverse effects on renal system and blood pressures Effects of Pb on reproductive
system have been studied intensively, e.g. other pregnancy outcome and pregnancy
hypertension.
However, the relationship between the severity of pre-eclampsia and heavy metal levels have
not been investigated.
The purpose of this study, to investigate whether severity of preeclampsia is associated
with altered levels of heavy metals (Cd, Hg, arsenic and Pb) in maternal blood, fetal blood,
and maternal hair.
;
Observational Model: Ecologic or Community, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04725812 -
Complement Regulation to Undo Systemic Harm in Preeclampsia
|
Phase 2 | |
| Active, not recruiting |
NCT03744988 -
Serum Androgen Levels as a Marker for the Severity of Preeclampsia
|
||
| Completed |
NCT02189148 -
First-trimester Prediction of Preeclampsia
|
||
| Completed |
NCT04058405 -
Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Preeclampsia
|
||
| Completed |
NCT03164304 -
Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia
|
Phase 4 | |
| Not yet recruiting |
NCT06265415 -
Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine
|
N/A | |
| Completed |
NCT02379832 -
Pre-Eclampsia And Growth Restriction: a Longitudinal Study
|
||
| Not yet recruiting |
NCT01538121 -
Antiphospholipid Antibodies and Early Severe Preeclampsia.
|
N/A | |
| Recruiting |
NCT01382732 -
Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia
|
Phase 3 | |
| Completed |
NCT01408979 -
Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia
|
Phase 4 | |
| Completed |
NCT01538147 -
Restless Leg Syndrome and Severe Preeclampsia
|
N/A | |
| Terminated |
NCT03008616 -
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
|
Phase 2/Phase 3 |